tbuckley/cabot-search huggingface dataset:
Irritant contact dermatitis in healthcare workers as a result of the COVID-19 pandemic
Authors: L. Kiely, E. Moloney, G. O'Sullivan, J. Eustace, J. Gallagher, J. F. Bourke
Journal: British Journal of Dermatology (2020)

Healthcare providers at the forefront of the COVID-19 response are at constant risk of infection  International guidance recommends frequent handwashing and personal protective equipment (PPE) to help prevent contraction and transmission of the virus  However, evidence is emerging that these practices are causing adverse effects on the skin integrity of frontline healthcare workers (HCWs)  This study aims to evaluate the degree of COVID-19-related dermatitis among frontline staff members from a large tertiary hospital in Ireland  A single-centre cross-sectional study of HCWs from a university hospital in Ireland was undertaken between 29 April and 13 May 2020  Approximately, 1000 online and paper surveys were distributed to hospital staff  Participants reported on the duration of PPE exposure, change in handwashing practices, symptoms of dermatitis and alleviating measures trialled  Data were collected in Microsoft Excel and the results were analysed using SPSS  Of the 270 participants in this study, 223 (82 6%) reported signs and symptoms of dermatitis  Hands were the most commonly affected site (76 5%) followed by the nose (13 7%) and cheeks (12 5%)  The most frequently reported symptom was dry skin, with 75 4% of staff affected  Redness was described by 36 9% and 27 6% complained of itching  Virtually all (n = 268;99 2%) HCWs reported an increase in frequency of handwashing;however, 122 (45 2%) staff members denied using emollients or other topical treatment  Atopy was not related to the development of dermatitis, but a personal history of dermatitis contributed significantly, with 55 (24 7%) of the dermatitis group citing a history of dermatitis vs  4 3% of unaffected staff (P < 0 001)  The dermatitis group recorded wearing PPE for an average of 3 15 h in comparison with the nondermatitis group using continuous PPE for 1 97 h;however, this fell short of significance (P = 0 211)  COVID-19 healthcare-related dermatitis is emerging as a significant problem  It is vital to promote awareness of this issue in order to provide appropriate prevention and timely treatment for our healthcare staff on the front line
Oral Drug Approved for Spinal Muscular Atrophy
Authors: Mary Chris Jaklevic
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Case 29-2020: A 66-Year-Old Man with Fever and Shortness of Breath after Liver Transplantation
Authors: Jay A. Fishman, Matthew B. Roberts, Eric W. Zhang, Deepali Kumar, Hans H. Hirsch, Umberto Maggiore
Journal: New England Journal of Medicine (2020)

A Man with Fever and Shortness of Breath after Liver Transplantation A 66-year-old man with hypertension, diabetes, hyperlipidemia, obesity, chronic kidney disease, and end-stage liver disease, for...
Correction to: Deciphering cellular transcriptional alterations in Alzheimer’s disease brains
Authors: Xue Wang, Mariet Allen, Shaoyu Li, Zachary S. Quicksall, Tulsi A. Patel, Troy P. Carnwath, Joseph S. Reddy, Minerva M. Carrasquillo, Sarah J. Lincoln, Thuy T. Nguyen, Kimberly G. Malphrus, Dennis W. Dickson, Julia E. Crook, Yan W. Asmann, Nilüfer Ertekin-Taner
Journal: Molecular Neurodegeneration (2020)

An amendment to this paper has been published and can be accessed via the original article.
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153
Authors: David M. Waterhouse, Edward B. Garon, Jason Chandler, Michael McCleod, Maen Hussein, Robert Jotte, Leora Horn, Davey B. Daniel, George Keogh, Ben Creelan, Lawrence H. Einhorn, Justin Baker, Samer Kasbari, Petros Nikolinakos, Sunil Babu, Felix Couture, Natasha B. Leighl, Craig Reynolds, George Blumenschein, Vijay Gunuganti, Ang Li, Nivedita Aanur, David R. Spigel
Journal: Journal of Clinical Oncology (2020)

PURPOSE Limited data exist on the optimal duration of immunotherapy, including for non–small-cell lung cancer (NSCLC). We present an exploratory analysis of CheckMate 153, a largely community-based phase IIIb/IV study, to evaluate the impact of 1-year fixed-duration versus continuous therapy on the efficacy and safety of nivolumab. METHODS Patients with previously treated advanced NSCLC received nivolumab monotherapy (3 mg/kg every 2 weeks). Those still receiving treatment at 1 year, including patients perceived to be deriving benefit despite radiographic progression, were randomly assigned to continue nivolumab until disease progression or unacceptable toxicity or to stop nivolumab with the option of on-study retreatment after disease progression (1-year fixed duration). RESULTS Of 1,428 patients treated, 252 were randomly assigned to continuous (n = 127) or 1-year fixed-duration (n = 125) treatment (intent-to-treat [ITT] population). Of these, 89 and 85 patients in the continuous and 1-year fixed-duration arms, respectively, had not progressed (progression-free survival [PFS] population). With minimum post–random assignment follow-up of 13.5 months, median PFS was longer with continuous versus 1-year fixed-duration treatment (PFS population: 24.7 months v 9.4 months; hazard ratio [HR], 0.56 [95% CI, 0.37 to 0.84]). Median overall survival from random assignment was longer with continuous versus 1-year fixed-duration treatment in the PFS (not reached v 32.5 months; HR, 0.61 [95% CI, 0.37 to 0.99]) and ITT (not reached v 28.8 months; HR, 0.62 [95% CI, 0.42 to 0.92]) populations. Few new-onset treatment-related adverse events occurred. No new safety signals were identified. CONCLUSION To our knowledge, these findings from an exploratory analysis represent the first randomized data on continuous versus fixed-duration immunotherapy in previously treated advanced NSCLC and suggest that continuing nivolumab beyond 1 year improves outcomes.
Covid-19: Doctors call for public inquiry into UK government’s handling of pandemic
Authors: Abi Rimmer
Journal: BMJ (2020)

The UK government's handling of the covid-19 pandemic, including its testing strategy, must be subject to a public inquiry, doctors have said.Delegates attending the virtual BMA annual representative meeting on 15 September voted overwhelmingly in favour of a motion that called for an inquiry to allow the UK to be better prepared for future pandemics.
Impaired NHEJ repair in amyotrophic lateral sclerosis is associated with TDP-43 mutations
Authors: Anna Konopka, Donna R. Whelan, Md Shafi Jamali, Emma Perri, Hamideh Shahheydari, Reka P. Toth, Sonam Parakh, Tina Robinson, Alison Cheong, Prachi Mehta, Marta Vidal, Audrey M. G. Ragagnin, Ivan Khizhnyak, Cyril J. Jagaraj, Jasmin Galper, Natalie Grima, Anand Deva, Sina Shadfar, Garth A. Nicholson, Shu Yang, Suzanne M. Cutts, Zuzana Horejsi, Toby D. M. Bell, Adam K. Walker, Ian P. Blair, Julie D. Atkin
Journal: Molecular Neurodegeneration (2020)

Abstract Background Pathological forms of TAR DNA-binding protein 43 (TDP-43) are present in motor neurons of almost all amyotrophic lateral sclerosis (ALS) patients, and mutations in TDP-43 are also present in ALS. Loss and gain of TDP-43 functions are implicated in pathogenesis, but the mechanisms are unclear. While the RNA functions of TDP-43 have been widely investigated, its DNA binding roles remain unclear. However, recent studies have implicated a role for TDP-43 in the DNA damage response. Methods We used NSC-34 motor neuron-like cells and primary cortical neurons expressing wildtype TDP-43 or TDP-43 ALS associated mutants (A315T, Q331K), in which DNA damage was induced by etoposide or H 2 O 2 treatment. We investigated the consequences of depletion of TDP-43 on DNA repair using small interfering RNAs. Specific non homologous end joining (NHEJ) reporters (EJ5GFP and EJ2GFP) and cells lacking DNA-dependent serine/threonine protein kinase (DNA-PK) were used to investigate the role of TDP-43 in DNA repair. To investigate the recruitment of TDP-43 to sites of DNA damage we used single molecule super-resolution microscopy and a co-immunoprecipitation assay. We also investigated DNA damage in an ALS transgenic mouse model, in which TDP-43 accumulates pathologically in the cytoplasm. We also examined fibroblasts derived from ALS patients bearing the TDP-43 M337V mutation for evidence of DNA damage. Results We demonstrate that wildtype TDP-43 is recruited to sites of DNA damage where it participates in classical NHEJ DNA repair. However, ALS-associated TDP-43 mutants lose this activity, which induces DNA damage. Furthermore, DNA damage is present in mice displaying TDP-43 pathology, implying an active role in neurodegeneration. Additionally, DNA damage triggers features typical of TDP-43 pathology; cytoplasmic mis-localisation and stress granule formation. Similarly, inhibition of NHEJ induces TDP-43 mis-localisation to the cytoplasm. Conclusions This study reveals that TDP-43 functions in DNA repair, but loss of this function triggers DNA damage and is associated with key pathological features of ALS.
Exosomes secreted by hiPSC-derived cardiac cells improve recovery from myocardial infarction in swine
Authors: Ling Gao, Lu Wang, Yuhua Wei, Prasanna Krishnamurthy, Gregory P. Walcott, Philippe Menasché, Jianyi Zhang
Journal: Science Translational Medicine (2020)

Cardiac cells differentiated from human induced pluripotent stem cells produce exosomes that improve recovery from myocardial infarction in pigs.
SARS-CoV-2 Infection Among Hospitalized Pregnant Women: Reasons for Admission and Pregnancy Characteristics — Eight U.S. Health Care Centers, March 1–May 30, 2020
Authors: Lakshmi Panagiotakopoulos, Tanya R. Myers, Julianne Gee, Heather S. Lipkind, Elyse O. Kharbanda, Denison S. Ryan, Joshua T.B. Williams, Allison L. Naleway, Nicola P. Klein, Simon J. Hambidge, Steven J. Jacobsen, Jason M. Glanz, Lisa A. Jackson, Tom T. Shimabukuro, Eric S. Weintraub
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

This report describes that the prevalences of prepregnancy obesity and gestational diabetes were higher among pregnant women hospitalized for COVID-19–related illness than among those admitted for pregnancy-related treatment or procedures and found to have COVID-19.
Operation Moonshot: Leaked documents prompt questions over cost, evidence, and reliance on private sector
Authors: Gareth Iacobucci
Journal: BMJ (2020)

The UK government’s plans to carry out up to 10 million covid-19 tests a day by early next year as part of a £100bn expansion of its national testing programme raise many questions <b>Gareth Iacobucci</b> examines the leaked documents
In ACS, prasugrel reduces 30-day MACE and mortality vs. ticagrelor or clopidogrel; no differences for major bleeding
Authors: Islam Y. Elgendy
Journal: Annals of Internal Medicine (2020)

Baldetti L, Melillo F, Moroni F, et al. Meta-analysis comparing P2Y12 inhibitors in acute coronary syndrome. Am J Cardiol. 2020;125;1815-22. 32305225.
Chloroquine Sensitizes<i>GNAQ/11</i>-mutated Melanoma to MEK1/2 Inhibition
Authors: Amanda Truong, Jae Hyuk Yoo, Michael T. Scherzer, John Michael S. Sanchez, Kali J. Dale, Conan G. Kinsey, Jackson R. Richards, Donghan Shin, Phaedra C. Ghazi, Michael D. Onken, Kendall J. Blumer, Shannon J. Odelberg, Martin McMahon
Journal: Clinical Cancer Research (2020)

Abstract Purpose: Mutational activation of GNAQ or GNA11 (GNAQ/11), detected in &amp;gt;90% of uveal melanomas, leads to constitutive activation of oncogenic pathways, including MAPK and YAP. To date, chemo- or pathway-targeted therapies, either alone or in combination, have proven ineffective in the treatment of patients with metastatic uveal melanoma. Experimental Design: We tested the efficacy of chloroquine or hydroxychloroquine, in combination with MAPK pathway inhibition in GNAQ/11-mutated cells in vitro and in vivo and identified mechanisms of MEK1/2 inhibitor plus chloroquine-induced cytotoxicity. Results: Inhibition of GNAQ/11-mediated activation of MAPK signaling resulted in the induction of autophagy. Combined inhibition of Gα and autophagy or lysosome function resulted in enhanced cell death. Moreover, the combination of MEK1/2 inhibition, using trametinib, with the lysosome inhibitor, chloroquine, also increased cytotoxicity. Treatment of mice bearing GNAQ/11-driven melanomas with trametinib plus hydroxychloroquine resulted in inhibition of tumor growth and significantly prolonged survival. Interestingly, lysosomal- and autophagy-specific inhibition with bafilomycin A1 was not sufficient to promote cytotoxicity in combination with trametinib. However, the addition of YAP inhibition with trametinib plus bafilomycin A1 resulted in cell death at comparable levels to trametinib plus chloroquine (T/CQ) treatment. Furthermore, T/CQ-treated cells displayed decreased YAP nuclear localization and decreased YAP transcriptional activity. Expression of a constitutively active YAP5SA mutant conferred resistance to T/CQ-induced cell death. Conclusions: These results suggest that YAP, MEK1/2, and lysosome function are necessary and critical targets for the therapy of GNAQ/11-driven melanoma, and identify trametinib plus hydroxychloroquine as a potential treatment strategy for metastatic uveal melanoma.
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
Authors: Catherine S. Grasso, Jennifer Tsoi, Mykola Onyshchenko, Gabriel Abril-Rodriguez, Petra Ross-Macdonald, Megan Wind-Rotolo, Ameya Champhekar, Egmidio Medina, Davis Y. Torrejon, Daniel Sanghoon Shin, Phuong Tran, Yeon Joo Kim, Cristina Puig-Saus, Katie Campbell, Agustin Vega-Crespo, Michael Quist, Christophe Martignier, Jason J. Luke, Jedd D. Wolchok, Douglas B. Johnson, Bartosz Chmielowski, F. Stephen Hodi, Shailender Bhatia, William Sharfman, Walter J. Urba, Craig L. Slingluff, Adi Diab, John B.A.G. Haanen, Salvador Martin Algarra, Drew M. Pardoll, Valsamo Anagnostou, Suzanne L. Topalian, Victor E. Velculescu, Daniel E. Speiser, Anusha Kalbasi, Antoni Ribas
Journal: Cancer Cell (2020)
Germline mutational profile of Chinese patients under 70 years old with colorectal cancer
Authors: Teng‐Jia Jiang, Fang Wang, Ying‐Nan Wang, Jia‐Jia Hu, Pei‐Rong Ding, Jun‐Zhong Lin, Zhi‐Zhong Pan, Gong Chen, Jian‐Yong Shao, Rui‐hua Xu, Qi Zhao, Feng Wang
Journal: Cancer Communications (2020)

Abstract Background Inherited susceptibility accounts for nearly one‐third of colorectal cancer (CRC) predispositions and has an 80%‐100% lifetime risk of this disease. However, there are few data about germline mutations of hereditary CRC‐related genes in Chinese patients with CRC. This study aimed to assess the prevalence of gene mutations related to cancer susceptibility among Chinese patients with CRC, differences between Chinese and Western patients, and the phenotype‐genotype correlation. Methods We retrospectively collected tumor samples from 526 patients with CRC under 70 years old who underwent hereditary CRC genetic testing. A series of bioinformatic analyses, as well as statistical comparisons, were performed. Results We found that 77 patients (14.6%) harbored functional variants of the 12 genes. The mutation frequencies of the top 5 mutated genes were 6.5% for MutL homolog 1 ( MLH1 ), 5.1% for MutS homolog 2 ( MSH2 ), 1.0% for MSH6 , 0.8% for PMS1 homolog 2 ( PMS2 ), and 0.8% for APC regulator of the WNT signaling pathway ( APC ). Our data showed much higher rates of mutations of MSH6 and PMS2 genes among all mismatch repair (MMR) genes as compared with those in Western populations. Mutations in MLH1 , MSH2 , and MSH6 were found to be mutually exclusive. Patients with MLH1 or MSH2 mutations had higher frequencies of personal history of cancer ( MLH1 : 20.6% vs. 8.7%; MSH2 : 25.9% vs. 8.6%) and family history of cancer than those without these mutations ( MLH1 : 73.5% vs. 48.4%; MSH2 : 70.4% vs. 48.9%), and the lesions were more prone to occur on the right side of the colon than on the left side ( MLH1 : 73.5% vs. 29.3%; MSH2 : 56.0% vs. 31.0%). The proportion of stage I/II disease was higher in patients with MLH1 mutations than in those without MLH1 mutations (70.6% vs. 50.7%), and the rate of polyps was higher in patients with APC mutations than in those with wild‐type APC (75.0% vs. 17.4%). Conclusion These results provide a full‐scale landscape of hereditary susceptibility over 12 related genes in CRC patients and suggest that a comprehensive multi‐gene panel testing for hereditary CRC predisposition could be a helpful analysis in clinical practice.
Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials (vol 395, pg 1627, 2020)
Authors: Birgit Sawitzki, Paul N. Harden, Petra Reinke, Aurelie Moreau, James A. Hutchinson, David S. Game, Qizhi Tang, Eva C. Guinan, Manuela Battaglia, William J. Burlingham, Ian S. D. Roberts, Mathias Streitz, Regis Josien, Carsten A. Boeger, Cristiano Scotta, James F. Markmann, Joanna L. Hester, Karsten Juerchott, Cecile Braudeau, Ben James, Laura Contreras-Ruiz, Jeroen B. van der Net, Tobias Bergler, Rossana Caldara, William Petchey, Matthias Edinger, Nathalie Dupas, Michael Kapinsky, Ingrid Mutzbauer, Natalie M. Otto, Robert Oellinger, Maria P. Hernandez-Fuentes, Fadi Issa, Norbert Ahrens, Christoph Meyenberg, Sandra Karitzky, Ulrich Kunzendorf, Stuart J. Knechtle, Josep Grinyo, Peter J. Morris, Leslie Brent, Andrew Bushell, Laurence A. Turka, Jeffrey A. Bluestone, Robert I. Lechler, Hans J. Schlitt, Stephan Schlickeiser, Maria C. Cuturi, Peter J. Friend, Tewfik Miloud, Alexander Scheffold, Antonio Secchi, Kerry Crisalli, Sang-Mo Kang, Rachel Hilton, Bernhard Banas, Gilles Blancho, Hans-Dieter Volk, Giovanna Lombardi, Kathryn J. Wood, Edward K. Geissler
Journal: The Lancet (2020)
ADSCs-derived extracellular vesicles alleviate neuronal damage, promote neurogenesis and rescue memory loss in mice with Alzheimer's disease
Authors: Xinyi Ma, Meng Huang, Mengna Zheng, Chengxiang Dai, Qingxiang Song, Qian Zhang, Qian Li, Xiao Gu, Huan Chen, Gan Jiang, Ye Yu, Xuesong Liu, Suke Li, Gang Wang, Hongzhuan Chen, Liangjing Lu, Xiaoling Gao
Journal: Journal of Controlled Release (2020)

Despite the various mechanisms that involved in the pathogenesis of Alzheimer's disease (AD), neuronal damage and synaptic dysfunction are the key events leading to cognition impairment. Therefore, neuroprotection and neurogenesis would provide essential alternatives to the rescue of AD cognitive function. Here we demonstrated that extracellular vesicles secreted from adipose-derived mesenchymal stem cells (ADSCs-derived EVs, abbreviated as EVs) entered the brain quickly and efficiently following intranasal administration, and majorly accumulated in neurons within the central nervous system (CNS). Proteomics analysis showed that EVs contained multiple proteins possessing neuroprotective and neurogenesis activities, and neuronal RNA sequencing showed genes enrichment in neuroprotection and neurogenesis following the treatment with EVs. As a result, EVs exerted powerful neuroprotective effect on Aβ1–42 oligomer or glutamate-induced neuronal toxicity, effectively ameliorated neurologic damage in the whole brain areas, remarkably increased newborn neurons and powerfully rescued memory deficits in APP/PS1 transgenic mice. EVs also reduced Aβ deposition and decreased microglia activation although in a less extent. Collectively, here we provide direct evidence that ADSCs-derived EVs may potentially serve as an alternative for AD therapy through alleviating neuronal damage and promoting neurogenesis.
Addressing Childhood Poverty in Pediatric Clinical Settings
Authors: Margaret G. Parker, Arvin Garg, Margaret A. McConnell
Journal: JAMA Pediatrics (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Potential human transmission of amyloid β pathology: surveillance and risks
Authors: Elsa Lauwers, Giovanna Lalli, Sebastian Brandner, John Collinge, Veerle Compernolle, Charles Duyckaerts, Gustaf Edgren, Stéphane Haïk, John Hardy, Adel Helmy, Adrian J Ivinson, Zane Jaunmuktane, Mathias Jucker, Richard Knight, Robin Lemmens, I-Chun Lin, Seth Love, Simon Mead, V Hugh Perry, James Pickett, Guy Poppy, Sheena E Radford, Frederic Rousseau, Carol Routledge, Giampietro Schiavo, Joost Schymkowitz, Dennis J Selkoe, Colin Smith, Dietmar R Thal, Tom Theys, Pierre Tiberghien, Peter van den Burg, Philippe Vandekerckhove, Clare Walton, Hans L Zaaijer, Henrik Zetterberg, Bart De Strooper
Journal: The Lancet Neurology (2020)
Biopsy Cell Cycle Proliferation Score Predicts Adverse Surgical Pathology in Localized Renal Cell Carcinoma
Authors: Jeffrey J. Tosoian, Adam S. Feldman, Madeline R. Abbott, Rohit Mehra, Placede Tiemeny, J. Stuart Wolf, Steven Stone, Shulin Wu, Stephanie Daignault-Newton, Jeremy M.G. Taylor, Chin-Lee Wu, Todd M. Morgan
Journal: European Urology (2020)
A regulatory T cell Notch4–GDF15 axis licenses tissue inflammation in asthma
Authors: Hani Harb, Emmanuel Stephen-Victor, Elena Crestani, Mehdi Benamar, Amir Massoud, Ye Cui, Louis-Marie Charbonnier, Sena Arbag, Safa Baris, Amparito Cunnigham, Juan Manuel Leyva-Castillo, Raif S. Geha, Amirhosein J. Mousavi, Boris Guennewig, Klaus Schmitz-Abe, Constantinos Sioutas, Wanda Phipatanakul, Talal A. Chatila
Journal: Nature Immunology (2020)